Clinical Significance of Serum VEGF-C Level and C-erbB-2 Protein Expression in Patients with Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

HUANG Guilin ¹ , HOU Jixue ² , WU Yiping ¹

1.Department of Plastic Surgery, The Affiliated Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;;
2.Department of Gastrointestinal and Breast Surgery, The First Affiliated Hospital of Medical College of Shihezi University, Xinjiang, Shihezi 832008, China;

Corresponding author：

Keywords：

Breast cancer; Serum; Vascular endothelial growth factor C; C-erbB-2; Differential diagnosis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate clinical significance of serum VEGF-C level and C-erbB-2 protein expression in patients with breast cancer.
Methods Sixty-two female patients with breast invasive ductal cancer and breast benign lesion were respectively selected. Serum VEGF-C level was detected by enzyme-linked immunosorbent assay (ELISA) before operation and at one month after operation, and C-erbB-2 protein expression in tissues of breast cancer was detected by immunohistochemistry. Then, the relationship between serum VEGF-C level and clinicopathologic characteristics and C-erbB-2 protein expressions wereas analyzed.
Results The serum VEGF-C level before operation in breast cancer patients〔(279.65±17.34) pg/ml〕 was significantly higher than that in breast benign lesions patients 〔(167.26±12.15) pg/ml〕, P＜0.01. In breast cancer patients, the serum VEGF-C level before operation was higher than that at one month after operation 〔(209.45±15.23) pg/ml〕, P＜0.01. The serum VEGF level was related to tumor stage (P＜0.05) but not to patient age, tumor size, menopause status , lymph node metastasis or not and ER and PR expression (P gt;0.05). The positive expression rate of C-erbB-2 protein in breast cancer patients (54.84%, 34/62) was significantly higher than that in breast benign lesion patients (11.29%, 7/62), P＜0.01. Moreover, the positive expression rate of C-erbB-2 protein in breast cancer patients with axilla lymph node metastasis (69.44%) was significantly higher than that without axilla lymph node metastases (34.62%), P＜0.05. The serum VEGF level increased with increasing expression intensity of C-erbB-2 protein and there was positive correlation between them (r=0.813，P＜0.05).
Conclusions The serum VEGF-C level in breast cancer may be conducted as an assisted marker to differential diagnosis of breast tumor. C-erbB-2 is related to lymph node metastasis of breast cancer patients. There is synergistic effect between VEGF-C and C-erbB-2 in the lymph node metastasis way of breast cancer.

Citation： HUANG Guilin,HOU Jixue,WU Yiping. Clinical Significance of Serum VEGF-C Level and C-erbB-2 Protein Expression in Patients with Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2009, 16(7): 514-517. doi: Copy

1.	李树玲主编. 乳腺肿瘤学 [M]. 第1版. 北京：科学技术文献出版社， 2000： 392393.
2.	Birner P, Oberhuber G, Satni J, et al. Evaluation of the United States Food and Drug Administrationapproved scoring and test system of HER2 protein expression in breast cancer [Ｊ]. Clin Cancer Res, 2001; 7(6): 16691675.
3.	Nathanson SD. Insights into the mechanisms of lymph node metastasis [Ｊ]. Cancer, 2003; 98(2): 413423.
4.	Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma：correlation with clinicopathologic parameters and VEGFfamily gene expression [Ｊ]. Mod Pathol, 2005; 18(1): 143152.
5.	Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factorCmediated lymphangiogenesis promotes tumour metastasis [Ｊ]. EMBO J, 2001; 20(4): 672682.
6.	Bando H, Weich HA, Horiguchi S, et al. The association between vascular endothelial growth factorC, its corresponding receptor, VEGFR3, and prognosis in primary breast cancer: a study with 193 cases [Ｊ]. Oncol Rep, 2006; 15(3): 653659.
7.	Mylona E, Alexandrou P, Mpakali A, et al. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)C and D and VEGF receptor 3 in invasive breast carcinoma [Ｊ]. Eur J Surg Oncol, 2007; 33(3): 294300.
8.	梁燕，姜军，王清良，等. 自制组织芯片研究VEGFC在乳腺癌中的表达及其意义 [Ｊ]. 中国普外基础与临床杂志, 2006; 13(5): 580584.
9.	Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGFC levels as tumor markers in patients with cervical carcinoma [Ｊ]. Cancer, 2005; 103(4): 724730.
10.	Zhang XH, Huang D, Guo GL, et al. Coexpression of VEGFC and COX2 and its association with lymphangiogenesis in human breast cancer [Ｊ]. BMC Cancer, 2008; 8: 4.
11.	Siriwardena BS, Kudo Y, Ogawa I, et al. VEGFC is associated with lymphatic status and invasion in oral cancer [Ｊ]. J Clin Pathol, 2008; 61(1): 103108.
12.	Yavuz S, Paydas S, Disel U, et al. VEGFC expression in breast cancer: clinical importance [Ｊ]. Adv Ther, 2005; 22(4): 368380.
13.	Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER2/erbB2/cneu (HER2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662 [Ｊ].Clin Cancer Res, 2001; 7(9): 27032711.
14.	Tanner M, Jrvinen P, Isola J. Amplification of HER2/neu and topoisomerase II in primary and metastatic breast cancer [Ｊ]. Cancer Res, 2001; 61(14): 53455348.
15.	Pienkowski T, Olszewski W, Kraszewakas E, et al. Predictive value of HER2 receptor, P53, bcl2 and bax proteins, MB1 antibody, estrogene and progesterone receptor expression in breast cancer patients receiving adjuvant tamoxifen [Ｊ]. Eur J Cancer, 2002; 38(l3): 116119.
16.	蔡春友，付金瑞，刘妍菊，等. 乳腺癌NFkB HER2 VEGFC与VEGFR3表达及其意义 [Ｊ]. 中国肿瘤临床, 2005; 32 (23): 13331337.

1. 李树玲主编. 乳腺肿瘤学 [M]. 第1版. 北京：科学技术文献出版社， 2000： 392393.
2. Birner P, Oberhuber G, Satni J, et al. Evaluation of the United States Food and Drug Administrationapproved scoring and test system of HER2 protein expression in breast cancer [Ｊ]. Clin Cancer Res, 2001; 7(6): 16691675.
3. Nathanson SD. Insights into the mechanisms of lymph node metastasis [Ｊ]. Cancer, 2003; 98(2): 413423.
4. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma：correlation with clinicopathologic parameters and VEGFfamily gene expression [Ｊ]. Mod Pathol, 2005; 18(1): 143152.
5. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factorCmediated lymphangiogenesis promotes tumour metastasis [Ｊ]. EMBO J, 2001; 20(4): 672682.
6. Bando H, Weich HA, Horiguchi S, et al. The association between vascular endothelial growth factorC, its corresponding receptor, VEGFR3, and prognosis in primary breast cancer: a study with 193 cases [Ｊ]. Oncol Rep, 2006; 15(3): 653659.
7. Mylona E, Alexandrou P, Mpakali A, et al. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)C and D and VEGF receptor 3 in invasive breast carcinoma [Ｊ]. Eur J Surg Oncol, 2007; 33(3): 294300.
8. 梁燕，姜军，王清良，等. 自制组织芯片研究VEGFC在乳腺癌中的表达及其意义 [Ｊ]. 中国普外基础与临床杂志, 2006; 13(5): 580584.
9. Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGFC levels as tumor markers in patients with cervical carcinoma [Ｊ]. Cancer, 2005; 103(4): 724730.
10. Zhang XH, Huang D, Guo GL, et al. Coexpression of VEGFC and COX2 and its association with lymphangiogenesis in human breast cancer [Ｊ]. BMC Cancer, 2008; 8: 4.
11. Siriwardena BS, Kudo Y, Ogawa I, et al. VEGFC is associated with lymphatic status and invasion in oral cancer [Ｊ]. J Clin Pathol, 2008; 61(1): 103108.
12. Yavuz S, Paydas S, Disel U, et al. VEGFC expression in breast cancer: clinical importance [Ｊ]. Adv Ther, 2005; 22(4): 368380.
13. Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER2/erbB2/cneu (HER2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662 [Ｊ].Clin Cancer Res, 2001; 7(9): 27032711.
14. Tanner M, Jrvinen P, Isola J. Amplification of HER2/neu and topoisomerase II in primary and metastatic breast cancer [Ｊ]. Cancer Res, 2001; 61(14): 53455348.
15. Pienkowski T, Olszewski W, Kraszewakas E, et al. Predictive value of HER2 receptor, P53, bcl2 and bax proteins, MB1 antibody, estrogene and progesterone receptor expression in breast cancer patients receiving adjuvant tamoxifen [Ｊ]. Eur J Cancer, 2002; 38(l3): 116119.
16. 蔡春友，付金瑞，刘妍菊，等. 乳腺癌NFkB HER2 VEGFC与VEGFR3表达及其意义 [Ｊ]. 中国肿瘤临床, 2005; 32 (23): 13331337.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Significance of Serum VEGF-C Level and C-erbB-2 Protein Expression in Patients with Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content